US Patent 10,959,943: Scope, Claim Construction, Exclusivity, and Apomorphine Patent Landscape
US Patent 10,959,943 protects methods of treating Parkinson’s disease “off” episodes with a sublingual apomorphine film selected through patient uptitration and defined by pharmacokinetic performance. Its strongest protection is not the apomorphine molecule alone. The patent combines four elements: a multipart film, an acid addition salt of apomorphine, patient-specific dose titration, and specified plasma exposure limits.
The patent is directed to the KYNMOBI product concept, an apomorphine hydrochloride sublingual film approved by the FDA for acute intermittent treatment of “off” episodes in patients with Parkinson’s disease. The core claims require rapid exposure, a capped apomorphine Cmax, and, in one independent claim, sustained plasma concentration. The dependent claims add dosage strengths, film mechanical properties, permeation enhancers, polymer content, and antiemetic pretreatment.[1][2]
What does US Patent 10,959,943 protect?
US 10,959,943 is a method-of-treatment patent with formulation limitations. It does not claim every apomorphine formulation or every treatment of Parkinson’s disease.
| Claim group |
Principal subject matter |
Commercial relevance |
| Claims 1-6 |
Sublingual apomorphine film, uptitration, rapid exposure, Cmax below 10 ng/mL, specified strengths |
Core treatment and dose-regimen protection |
| Claims 7-8 |
Same treatment concept with antiemetic pretreatment |
Clinical-use and tolerability protection |
| Claims 9-27 |
Film toughness, permeation enhancers, polymer molecular weight, and disintegration time |
Formulation and manufacturing constraints |
| Claims 28-48 |
Counterpart limitations tied to claim 7 |
Anti-emetic and formulation protection |
| Claims 49-52 |
Dosage strengths tied to claim 2 |
Sustained-exposure dose protection |
The patent has three independent claims:
- Claim 1 requires an apomorphine film, uptitration, sublingual administration, plasma concentration of at least 2.64 ng/mL within 30 minutes, and Cmax below 10 ng/mL.
- Claim 2 requires the same general steps and exposure threshold, plus maintenance of at least 2.64 ng/mL for at least 60 minutes.
- Claim 7 requires the claim 1 exposure profile and administration of an effective antiemetic before the film.
The independent claims are cumulative method claims. A potentially infringing product or treatment protocol must satisfy every limitation of the applicable claim.
How should the independent claims be construed?
Claim 1: rapid onset with controlled peak exposure
Claim 1 requires four practical components:
- A film with a first portion containing an acid addition salt of apomorphine.
- A second portion containing a pH-neutralizing agent.
- Uptitration to determine the patient’s effective dose.
- Sublingual administration that produces an average concentration of at least 2.64 ng/mL within 30 minutes and a Cmax below 10 ng/mL.
The claim does not specify a single fixed dose. The dose is selected through uptitration. That structure allows the claim to cover multiple strengths, provided the administered film produces the claimed pharmacokinetic profile.
The “on average” language is significant. The pharmacokinetic limitations are expressed as population-level or study-level outcomes rather than a guaranteed result in every individual patient. In litigation, the patent owner would likely rely on clinical pharmacokinetic data, product specifications, dosing instructions, and controlled studies to establish whether the accused method produces the required average exposure.
Claim 2: sustained therapeutic exposure
Claim 2 adds a duration requirement: apomorphine plasma concentration must remain at or above 2.64 ng/mL for at least 60 minutes.
This limitation narrows the claim materially. A competing sublingual film could potentially meet claim 1 while avoiding claim 2 if it reaches the required concentration within 30 minutes but falls below the threshold before 60 minutes.
Claim 7: antiemetic pretreatment
Claim 7 requires administration of an effective amount of an antiemetic before administration of the film. Claim 8 specifies that the antiemetic is administered for at least two days before treatment.
This is a method-of-use limitation rather than a formulation limitation. A product may have the same film composition and pharmacokinetic profile but avoid claim 7 if the commercial treatment protocol does not require antiemetic pretreatment. That strategy would not necessarily avoid claims 1 or 2.
What formulations are protected by US 10,959,943?
The formulation claims cover a broad but technically defined film architecture.
Multipart film and pH neutralization
The film must have:
- A first portion containing an acid addition salt of apomorphine.
- A second portion containing a pH-neutralizing agent.
The claims do not expressly require a particular geometric arrangement, such as two separate layers, although the “first portion” and “second portion” language creates a structural distinction. A monolithic film with chemically distinguishable regions could raise the same issue as a visibly bilayer film, depending on the specification and prosecution history.
Apomorphine hydrochloride is the commercially relevant acid addition salt for KYNMOBI. A different acid addition salt could fall within the literal scope if it meets the claim language and produces the required performance.
Dosage-strength limitations
The claimed dose ranges are:
| Dependent claims |
Stated apomorphine salt amount |
| Claims 3, 28, 49 |
12.5 ± 2.5 mg |
| Claims 4, 29, 50 |
17.5 ± 2.5 mg |
| Claims 5, 30, 51 |
25.0 ± 5.0 mg |
| Claims 6, 31, 52 |
35 ± 10.0 mg |
These ranges are relatively broad. For example, the 12.5 mg limitation covers 10.0 to 15.0 mg, while the 35 mg limitation covers 25 to 45 mg.
Permeation enhancers
Claims 10-15 and 33-38 address permeation enhancers. The listed categories include:
- Menthol
- Ionic and nonionic surfactants
- Polysorbates
- Tocopherol derivatives
- Poloxamers
- Monoglycerides and diglycerides
- Fatty acids
- Fatty alcohols
Claim 15 and its counterpart claim 38 specifically identify menthol combined with glycerol monostearate.
The claims permit different placement of the permeation enhancer. It may be present in the second portion, the first portion, or both, subject to the dependent-claim structure. Claim 13 requires the first portion to be free of a permeation enhancer when dependent on claim 10.
Polymer limitations
Claims 16-25 and 39-48 divide polymers by molecular weight.
| Polymer category |
Claimed limitation |
| High molecular weight polymer |
At least 20% w/w; weight-average molecular weight of at least 60 kDa |
| Preferred high molecular weight range |
20% to 40% w/w; 60 kDa to 1,000 kDa |
| Low molecular weight polymer |
5% w/w or less; weight-average molecular weight below 60 kDa |
| Preferred low molecular weight range |
0.01% to 5% w/w; 5 kDa to 50 kDa |
| Named polymers |
Carboxymethylcellulose, hydroxypropyl cellulose, hydroxypropyl methyl cellulose, hydroxyethyl cellulose, and methyl cellulose |
Claim 24 specifically identifies hydroxypropyl cellulose as the low molecular weight polymer. Claim 25 excludes a pharmaceutically acceptable low molecular weight polymer from the second portion.
These limitations create potential design-around routes based on polymer identity, molecular weight, concentration, or location within the film.
Mechanical strength and disintegration
Claim 9 requires toughness of at least 100 g×mm. Claims 26 and 27 require disintegration in aqueous media within a window of 30 seconds to two minutes.
A competing film with equivalent drug delivery but materially different mechanical strength or disintegration behavior may avoid these dependent claims. Those changes would not necessarily avoid claims 1, 2, or 7, which do not expressly require the toughness or disintegration limitations.
When does US Patent 10,959,943 lose exclusivity?
The patent issued on March 30, 2021. Its ordinary patent term is generally measured from the earliest effective nonprovisional filing date in the priority chain, not from the issue date. The legally operative expiration date must account for the complete priority chain, terminal disclaimers, patent-term adjustment, and any applicable patent-term extension.[1]
The patent’s expiration date should therefore be taken from the USPTO patent-term record and the current FDA Orange Book entry rather than calculated solely from the issue date. Patent 10,959,943 is a continuation-family patent associated with the KYNMOBI apomorphine film program. Its commercial exclusion is separate from FDA orphan-drug exclusivity and from any other KYNMOBI patents.
A later expiration date for another patent in the same product family would not automatically extend the term of US 10,959,943. Each patent must be analyzed independently.
What is the Orange Book status of US 10,959,943?
US 10,959,943 is associated with KYNMOBI, whose active ingredient is apomorphine hydrochloride and whose dosage form is a sublingual film.[2][3]
The Orange Book analysis should distinguish:
- Drug-substance patents, if any.
- Formulation patents covering the film.
- Method-of-use patents covering treatment of “off” episodes.
- Patents covering dosing, titration, or pharmacokinetic performance.
US 10,959,943 is principally a method-of-use and formulation-performance patent. It does not broadly claim apomorphine as a chemical entity. Its commercial relevance depends on whether a generic applicant seeks approval for the same sublingual film and the same Parkinson’s disease indication.
Because the claims are method claims, a generic applicant may evaluate a Section viii statement that omits the patented method, where FDA labeling and the Orange Book listing permit that approach. A Section viii strategy is more difficult if the patented treatment is inseparable from the proposed labeling or if the listed patent is treated as covering the approved use.
What Paragraph IV challenges and litigation risks exist?
A Paragraph IV certification could challenge the patent as:
- Invalid for lack of novelty or obviousness.
- Indefinite because of the “on average” pharmacokinetic limitations.
- Unsupported or insufficiently enabled across the full claim scope.
- Not infringed because the proposed film lacks the claimed two-portion structure, pH-neutralizing agent, uptitration protocol, or exposure profile.
The strongest invalidity arguments would likely focus on combinations of earlier apomorphine films, buccal or sublingual delivery systems, pH-modifying excipients, and known apomorphine titration regimens. The strongest infringement case would require reliable evidence that the proposed product and labeling produce the specified pharmacokinetic profile.
The pharmacokinetic limitations create both value and litigation complexity. They narrow the claims against prior art, but they also create factual disputes over:
- The relevant patient population.
- The number of subjects required to establish an average.
- Whether “within 30 minutes” means a measured time point or any time during the first 30 minutes.
- Whether Cmax must be below 10 ng/mL for the effective dose in every study.
- Whether the claimed concentration is measured as apomorphine, total apomorphine, or a specified analytical form.
No biosimilar pathway applies. Apomorphine is a small-molecule active ingredient, so competitive entrants would use the ANDA pathway or, in some circumstances, an NDA pathway rather than the biosimilar framework under the Public Health Service Act.[4]
How strong is the patent estate for KYNMOBI?
The estate is strongest where a competitor copies the complete clinical and formulation profile:
- Sublingual film delivery.
- Apomorphine acid addition salt.
- Two-portion film with pH neutralization.
- Patient-specific uptitration.
- Rapid exposure to at least 2.64 ng/mL.
- Cmax below 10 ng/mL.
- Sustained exposure for at least 60 minutes, where applicable.
- Commercial dose strengths within the claimed ranges.
The estate is weaker against:
- Injectable apomorphine products.
- Oral or inhaled apomorphine products.
- A sublingual product using a materially different film architecture.
- A product with a different pH-control mechanism.
- A product whose pharmacokinetic profile does not meet the claimed thresholds.
- A treatment protocol that does not use the claimed uptitration or antiemetic steps.
The patent has meaningful claim layering. Claims 1, 2, and 7 provide separate independent routes to infringement. The dependent claims then target commercial implementation details. A design-around that defeats the formulation claims may still face the broader treatment claims if the pharmacokinetic and titration limitations remain satisfied.
How does KYNMOBI compare with competing Parkinson’s disease rescue therapies?
| Product |
Active ingredient |
Delivery |
Principal use |
Relationship to US 10,959,943 |
| KYNMOBI |
Apomorphine hydrochloride |
Sublingual film |
Acute “off” episodes |
Directly implicated |
| APOKYN |
Apomorphine hydrochloride |
Subcutaneous injection |
Acute “off” episodes |
Generally outside the claimed film limitations |
| INBRIJA |
Levodopa |
Inhalation powder |
Intermittent “off” episodes |
Different active ingredient and delivery system |
| Oral levodopa combinations |
Levodopa with adjuncts |
Oral tablets or capsules |
Baseline Parkinson’s treatment |
Generally outside the claimed film method |
APOKYN is the closest therapeutic comparator by active ingredient and rescue indication, but its injectable route avoids the central film limitations.[5] INBRIJA competes for the same intermittent “off” episode setting but uses inhaled levodopa and does not require an apomorphine film.[6]
What generic launch scenarios are most plausible?
Scenario 1: Same-film ANDA with Paragraph IV certification
This presents the highest infringement risk. A generic applicant would likely need to address the film structure, apomorphine salt, dose titration, PK profile, and any listed method-of-use claims.
Scenario 2: Same active ingredient with a different sublingual dosage form
A tablet, lozenge, spray, or non-film dosage form could avoid the film limitations but may encounter other patents or regulatory requirements. Bioequivalence and local absorption would remain important technical barriers.
Scenario 3: Sublingual film with redesigned excipients
A competitor could alter the pH-neutralizing agent, polymer system, permeation enhancer, disintegration time, or film architecture. This approach faces doctrine-of-equivalents risk if the redesigned elements perform substantially the same function in substantially the same way.
Scenario 4: Label carve-out
A generic applicant could attempt to omit the patented Parkinson’s disease method from labeling. This strategy depends on the Orange Book listing, the scope of the approved indication, FDA labeling requirements, and whether the remaining noninfringing use is substantial.
Key Takeaways
- US 10,959,943 is a method-of-treatment patent centered on a sublingual apomorphine film.
- Claims 1, 2, and 7 are the principal enforcement claims.
- Claim 1 requires rapid exposure and Cmax below 10 ng/mL.
- Claim 2 adds maintenance of at least 2.64 ng/mL for 60 minutes.
- Claim 7 adds antiemetic pretreatment.
- Dependent claims cover dose strengths, film toughness, permeation enhancers, polymer molecular weight, polymer concentration, and disintegration.
- Injectable apomorphine and inhaled levodopa products generally avoid the central film limitations.
- A generic sublingual film faces the greatest risk if it uses the same titration protocol and produces the claimed pharmacokinetic profile.
- No biosimilar pathway applies because apomorphine is a small-molecule drug.
- The exact enforceable expiration date must be determined from the USPTO term record and current Orange Book listing.
FAQs
Does US 10,959,943 cover apomorphine injections?
No. The asserted claims require a film and sublingual administration. Apomorphine injection products generally do not satisfy those limitations.
Does the patent require apomorphine hydrochloride hemihydrate?
The claims recite an acid addition salt of apomorphine. They do not, in the provided claim language, limit the salt to a particular hydrate or stoichiometric form.
Can a competing film avoid the patent by using a different dose?
Possibly. A different dose may avoid the listed dependent-strength claims, but it would not automatically avoid claims 1, 2, or 7 if the film still meets the structural, titration, administration, and pharmacokinetic limitations.
Is antiemetic pretreatment required for every claim?
No. It is required by claim 7 and claim 8’s narrower version. Claims 1 and 2 do not require antiemetic administration.
Does a film with a different permeation enhancer avoid all patent risk?
No. It may avoid specific dependent claims, such as claims 14, 15, 37, or 38, but claims 1 and 2 do not expressly require a particular permeation enhancer.
References
- United States Patent No. 10,959,943, “Methods of treating Parkinson’s disease,” issued March 30, 2021, United States Patent and Trademark Office.
- U.S. Food and Drug Administration. (2020). KYNMOBI (apomorphine hydrochloride) sublingual film prescribing information.
- U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations, Orange Book.
- U.S. Food and Drug Administration. (2024). Small business assistance: Frequently asked questions on the abbreviated new drug application process.
- U.S. Food and Drug Administration. (2020). APOKYN (apomorphine hydrochloride injection) prescribing information.
- U.S. Food and Drug Administration. (2018). INBRIJA (levodopa inhalation powder) prescribing information.